BACKGROUND/AIMS: Laryngotracheal stenosis is a rare but devastating proximal airway fibrosis that restricts a patient's ability to breathe. Treatment is primarily surgical and to date, there has never been a multi-institutional, randomized, prospective, and interventional clinical trial for a medical therapy to treat laryngotracheal stenosis. Therefore, we aimed to obtain patient feedback to guide successful trial design, recruitment, retention, and for identifying potential barriers to study participation. METHODS: Over 1000 members of an international laryngotracheal stenosis online support community (the Living with Idiopathic Subglottic Stenosis Facebook group) were sent two questionnaires for a proposed interventional double-blinded, randomized, placebo-controlled clinical trial. RESULTS: A total of 317 and 558 participants responded to the first and second surveys, respectively. The majority of participants (77%) were willing to consider enrollment, regardless of having a 50% chance of receiving placebo versus treatment (78%). The majority (84%) of participants were willing to travel 200 miles to participate for up to six in-person visits over 50 days. Specific side effects, including anemia/thrombocytopenia (72%) or risk of infection (69.3%) had the greatest impact on clinical trial participation with other side effects (peripheral edema (53%), oral ulcers (51%), and gastrointestinal side effects (41%)) having less impact. CONCLUSION: Patients with laryngotracheal stenosis possess nuanced insight into their disease and treatment options. As a group, they are extremely motivated for better therapies. Future laryngotracheal stenosis clinical trials should focus on providing excellent side effect -related education and utilizing feedback from online advocacy groups to optimize recruitment and retention.
BACKGROUND/AIMS: Laryngotracheal stenosis is a rare but devastating proximal airway fibrosis that restricts a patient's ability to breathe. Treatment is primarily surgical and to date, there has never been a multi-institutional, randomized, prospective, and interventional clinical trial for a medical therapy to treat laryngotracheal stenosis. Therefore, we aimed to obtain patient feedback to guide successful trial design, recruitment, retention, and for identifying potential barriers to study participation. METHODS: Over 1000 members of an international laryngotracheal stenosis online support community (the Living with Idiopathic Subglottic Stenosis Facebook group) were sent two questionnaires for a proposed interventional double-blinded, randomized, placebo-controlled clinical trial. RESULTS: A total of 317 and 558 participants responded to the first and second surveys, respectively. The majority of participants (77%) were willing to consider enrollment, regardless of having a 50% chance of receiving placebo versus treatment (78%). The majority (84%) of participants were willing to travel 200 miles to participate for up to six in-person visits over 50 days. Specific side effects, including anemia/thrombocytopenia (72%) or risk of infection (69.3%) had the greatest impact on clinical trial participation with other side effects (peripheral edema (53%), oral ulcers (51%), and gastrointestinal side effects (41%)) having less impact. CONCLUSION: Patients with laryngotracheal stenosis possess nuanced insight into their disease and treatment options. As a group, they are extremely motivated for better therapies. Future laryngotracheal stenosis clinical trials should focus on providing excellent side effect -related education and utilizing feedback from online advocacy groups to optimize recruitment and retention.
Authors: Alexander Gelbard; David O Francis; Vlad C Sandulache; John C Simmons; Donald T Donovan; Julina Ongkasuwan Journal: Laryngoscope Date: 2014-10-07 Impact factor: 3.325
Authors: C J Hartnick; B E Hartley; P D Lacy; J Liu; J A Bean; J P Willging; C M Myer; R T Cotton Journal: Arch Otolaryngol Head Neck Surg Date: 2001-10
Authors: Daniel Haik; Kevin Kashanchi; Sarah Tajran; Cameron Heilbronn; Catherine Anderson; David Oliver Francis; Alexander Gelbard; Sunil Pal Verma Journal: Ann Otol Rhinol Laryngol Date: 2019-01-04 Impact factor: 1.547
Authors: Robert C Griggs; Mark Batshaw; Mary Dunkle; Rashmi Gopal-Srivastava; Edward Kaye; Jeffrey Krischer; Tan Nguyen; Kathleen Paulus; Peter A Merkel Journal: Mol Genet Metab Date: 2008-11-13 Impact factor: 4.797
Authors: Kristen E Holm; Richard Casaburi; Scott Cerreta; Hélène A Gussin; Julian Husbands; Janos Porszasz; Valentin Prieto-Centurion; Robert A Sandhaus; Jamie L Sullivan; Linda J Walsh; Jerry A Krishnan Journal: Patient Date: 2016-06 Impact factor: 3.883
Authors: Sunil P Verma; Khodayar Goshtasbi; Lynne D Berry; Catherine Anderson; David O Francis; Alexander Gelbard Journal: Laryngoscope Date: 2020-09-29 Impact factor: 2.970